Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement

被引：25

作者：

Einhorn, LH

Rapoport, B

Koeller, J

Grunberg, SM

Feyer, P

Rittenberg, C

Aapro, M

机构：

[1] Indiana Univ, Sch Med, Div Hematol Oncol, Indianapolis, IN 46202 USA

[2] Med Oncol Ctr Rosebank, ZA-2193 Johannesburg, South Africa

[3] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA

[4] Univ Vermont, Med Ctr, Burlington, VT 05401 USA

[5] Viventes Clin Beniu Needcoellin, Clin Radiotherapy, Berlin, Germany

[6] Rittenberg Oncol Consultants, Metairie, LA 70005 USA

[7] Inst Multidisciplinaire Oncol, CH-1272 Genolier, Switzerland

来源：

SUPPORTIVE CARE IN CANCER | 2005年 / 13卷 / 02期

关键词：

5-HT3; antagonist; multiple-day chemotherapy; antiemetics; high-dose chemotherapy;

D O I：

10.1007/s00520-004-0704-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The objective of this paper is to evaluate the efficacy of modern antiemetic therapy for chemotherapy-induced nausea and vomiting for patients receiving multiple-day or high-dose chemotherapy. Published phase II and phase III studies as well as their personal experiences were evaluated by the authors to develop this consensus statement. The largest published experience with multiple-day chemotherapy is with 5-day cisplatin combination chemotherapy. The introduction of 5-HT3 antagonists greatly improved emetic control. However, day 4-5 nausea as well as delayed nausea and vomiting remains a clinical problem despite the inclusion of dexamethasone. A 5-HT3 antagonist plus dexamethasone is the preferred current option for patients receiving high-dose chemotherapy with stem cell transplant. However, the results do not appear as successful as for highly emetic standard-dose chemotherapy.

引用

页码：112 / 116

页数：5